Nika Art/Shutterstock
For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects
The global implications of Russia’s invasion of Ukraine won’t become clear for weeks, if not years, but the crisis is already causing consternation among biotech executives.
In the three decades since the end of the Cold War, companies and labs developing new drugs have increasingly relied on a handful of Ukrainian firms — and one large firm in particular, called Enamine — for several of the key steps that go into discovering a new molecule to put in clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
